Category:Antineoplastic agents

子分类

本分类有以下55个子分类，共有55个子分类。

分类“Antineoplastic agents”中的媒体文件

以下198个文件属于本分类，共198个文件。

• 
  (±)-Mitotane Enantiomers Structural Formulae.png 2,099 × 620；16 KB
  
• 
  1yy9.png 633 × 259；68 KB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s005.ogv 33秒, 800 × 400；9.71 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s006.ogv 33秒, 800 × 400；8.65 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s007.ogv 33秒, 800 × 400；8.83 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s008.ogv 33秒, 800 × 400；8.07 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s009.ogv 33秒, 800 × 400；7.89 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s010.ogv 33秒, 800 × 400；8.74 MB
  
• A-Cell-Based-Small-Molecule-Screening-Method-for-Identifying-Inhibitors-of-Epithelial-Mesenchymal-pone.0033183.s011.ogv 33秒, 800 × 400；7.34 MB
  
• A-chalcone-related-small-molecule-that-induces-methuosis-a-novel-form-of-non-apoptotic-cell-death-1476-4598-10-69-S1.ogv 1分0秒, 320 × 240；1 MB
  
• A-chalcone-related-small-molecule-that-induces-methuosis-a-novel-form-of-non-apoptotic-cell-death-1476-4598-10-69-S2.ogv 1分0秒, 320 × 240；580 KB
  
• A-Comprehensive-Panel-of-Three-Dimensional-Models-for-Studies-of-Prostate-Cancer-Growth-Invasion-pone.0010431.s013.ogv 1分6秒, 524 × 384；8.71 MB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s1.ogv 12秒, 512 × 480；348 KB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s2.ogv 12秒, 640 × 480；337 KB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s3.ogv 12秒, 640 × 480；600 KB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s4.ogv 40秒, 640 × 480；3.45 MB
  
• A-magnetic-anti-cancer-compound-for-magnet-guided-delivery-and-magnetic-resonance-imaging-srep09194-s5.ogv 13秒, 640 × 480；631 KB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s2.ogv 25秒, 1,920 × 1,080；8.73 MB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s3.ogv 6.3秒, 1,920 × 1,080；342 KB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s4.ogv 6.3秒, 1,920 × 1,080；1.05 MB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s5.ogv 3.2秒, 1,920 × 1,080；1.53 MB
  
• A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s6.ogv 3.2秒, 1,920 × 1,080；2.12 MB
  
• A-phenanthrene-derived-PARP-inhibitor-is-an-extra-centrosomes-de-clustering-agent-exclusively-1471-2407-11-412-S1.ogv 16秒, 428 × 428；975 KB
  
• A-phenanthrene-derived-PARP-inhibitor-is-an-extra-centrosomes-de-clustering-agent-exclusively-1471-2407-11-412-S2.ogv 2分10秒, 512 × 512；1.38 MB
  
• A-spheroid-toxicity-assay-using-magnetic-3D-bioprinting-and-real-time-mobile-device-based-imaging-srep13987-s2.ogv 21秒, 640 × 360；781 KB
  
• 
  Aceglatone.svg 512 × 471；25 KB
  
• Advances-in-establishment-and-analysis-of-three-dimensional-tumor-spheroid-based-functional-assays-1741-7007-10-29-S4.ogv 29秒, 853 × 480；3.22 MB
  
• Advances-in-establishment-and-analysis-of-three-dimensional-tumor-spheroid-based-functional-assays-1741-7007-10-29-S5.ogv 13秒, 853 × 480；795 KB
  
• Advances-in-establishment-and-analysis-of-three-dimensional-tumor-spheroid-based-functional-assays-1741-7007-10-29-S6.ogv 12秒, 853 × 480；270 KB
  
• 
  Anthramycin.svg 765 × 390；17 KB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s2.ogv 42秒, 320 × 240；2.8 MB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s3.ogv 59秒, 320 × 240；2.97 MB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s4.ogv 42秒, 320 × 240；2.22 MB
  
• Arsenic-trioxide-alters-the-differentiation-of-mouse-embryonic-stem-cell-into-cardiomyocytes-srep14993-s5.ogv 45秒, 320 × 240；805 KB
  
• Artificial-human-Met-agonists-based-on-macrocycle-scaffolds-ncomms7373-s2.ogv 15秒, 960 × 540；2.45 MB
  
• 
  Aumolertinib.svg 945 × 565；25 KB
  
• Autophagy-Facilitates-the-Development-of-Breast-Cancer-Resistance-to-the-Anti-HER2-Monoclonal-pone.0006251.s001.ogv 4.5秒, 1,024 × 576；225 KB
  
• Autophagy-Facilitates-the-Development-of-Breast-Cancer-Resistance-to-the-Anti-HER2-Monoclonal-pone.0006251.s002.ogv 4.4秒, 856 × 480；971 KB
  
• Autophagy-Facilitates-the-Development-of-Breast-Cancer-Resistance-to-the-Anti-HER2-Monoclonal-pone.0006251.s003.ogv 4.5秒, 856 × 480；1.19 MB
  
• 
  Avutometinib ball-and-stick 7MFD.png 2,909 × 1,500；639 KB
  
• 
  Avutometinib.svg 205 × 56；15 KB
  
• 
  Belvarafenib.svg 264 × 70；19 KB
  
• 
  Benzylguanine.svg 512 × 726；15 KB
  
• 
  BI 811283 ball-and-stick 5K3Y.png 1,979 × 1,200；532 KB
  
• 
  BI 811283.svg 184 × 124；11 KB
  
• 
  Biosynthesis of nonproteinogenic amino acid.png 432 × 693；12 KB
  
• 
  Brigimadlin.svg 810 × 550；39 KB
  
• 
  Bropirimine structure.png 730 × 596；7 KB
  
• 
  Bropirimine synthesis.png 1,647 × 266；10 KB
  
• 
  Cedazuridine.svg 615 × 285；13 KB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S3.ogv 21秒, 210 × 214；1.17 MB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S4.ogv 28秒, 210 × 214；663 KB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S5.ogv 28秒, 210 × 214；676 KB
  
• Characterization-of-AKT-independent-effects-of-the-synthetic-AKT-inhibitors-SH-5-and-SH-6-using-an-1471-2407-10-287-S6.ogv 28秒, 210 × 214；855 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x6.ogv 13秒, 204 × 204；216 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x7.ogv 8.5秒, 204 × 204；224 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x8.ogv 13秒, 204 × 204；304 KB
  
• Chemical-dissection-of-the-cell-cycle-probes-for-cell-biology-and-anti-cancer-drug-development-cddis2014420x9.ogv 19秒, 204 × 204；369 KB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s002.ogv 29秒, 672 × 512；2.94 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s003.ogv 33秒, 768 × 766；2.3 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s004.ogv 50秒, 768 × 576；6.85 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s005.ogv 32秒, 768 × 576；5.18 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s006.ogv 21秒, 1,114 × 460；13.17 MB
  
• Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s007.ogv 21秒, 487 × 618；720 KB
  
• 
  Daniquidone.svg 634 × 317；3 KB
  
• Darinaparsin-Is-a-Multivalent-Chemotherapeutic-Which-Induces-Incomplete-Stress-Response-with-pone.0027699.s001.ogv 26秒, 518 × 514；449 KB
  
• 
  Darinaparsin.svg 855 × 390；17 KB
  
• 
  Defactinib ball-and-stick 5MAH.png 2,445 × 2,000；841 KB
  
• 
  Defactinib.svg 512 × 393；9 KB
  
• 
  Dicycloplatin02.png 1,642 × 929；88 KB
  
• 
  Enloplatin.png 692 × 269；71 KB
  
• 
  Enloplatin.svg 115 × 62；6 KB
  
• 
  Enzyme data for 4-substituted analogs.jpg 938 × 504；49 KB
  
• 
  Enzyme data for monosubstituted 5-aryl analogs.jpg 1,173 × 866；98 KB
  
• 
  Epacadostat.svg 512 × 212；11 KB
  
• 
  Erbuzole structure.png 1,347 × 720；16 KB
  
• 
  Exisulind structure.svg 512 × 292；5 KB
  
• Exogenous-Ether-Lipids-Predominantly-Target-Mitochondria-pone.0031342.s006.ogv 28秒, 480 × 360；8.69 MB
  
• 
  Glasdegib.svg 512 × 188；5 KB
  
• 
  Golcadomide.svg 512 × 195；9 KB
  
• High-Throughput-Ratio-Imaging-to-Profile-Caspase-Activity-Potential-Application-in-Multiparameter-pone.0020114.s001.ogv 3.8秒, 502 × 501；1.2 MB
  
• High-Throughput-Ratio-Imaging-to-Profile-Caspase-Activity-Potential-Application-in-Multiparameter-pone.0020114.s002.ogv 3.9秒, 502 × 501；3.7 MB
  
• 
  Hitachimycin.svg 512 × 295；8 KB
  
• 
  Iberdomide.svg 512 × 180；8 KB
  
• 
  Ibritumomab tiuxetan structure.svg 434 × 201；61 KB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s1.ogv 9.0秒, 671 × 512；2.61 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s2.ogv 9.0秒, 671 × 512；2.91 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s3.ogv 9.0秒, 671 × 512；3.52 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s4.ogv 9.0秒, 671 × 512；3.27 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s5.ogv 9.0秒, 671 × 512；4.61 MB
  
• Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s6.ogv 9.0秒, 671 × 512；2.34 MB
  
• In-silico-Experimentation-of-Glioma-Microenvironment-Development-and-Anti-tumor-Therapy-pcbi.1002355.s015.ogv 0.0秒, 432 × 336；16.02 MB
  
• In-silico-Experimentation-of-Glioma-Microenvironment-Development-and-Anti-tumor-Therapy-pcbi.1002355.s016.ogv 0.0秒, 432 × 336；11.97 MB
  
• In-silico-Experimentation-of-Glioma-Microenvironment-Development-and-Anti-tumor-Therapy-pcbi.1002355.s017.ogv 0.0秒, 432 × 336；15.38 MB
  
• In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s5.ogv 12秒, 1,920 × 1,080；3.29 MB
  
• In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s6.ogv 12秒, 1,920 × 1,080；6.59 MB
  
• In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s7.ogv 12秒, 1,920 × 1,080；3.44 MB
  
• In-vivo-Bioimaging-as-a-Novel-Strategy-to-Detect-Doxorubicin-Induced-Damage-to-Gonadal-Blood-Vessels-pone.0023492.s003.ogv 1分29秒, 480 × 336；2.73 MB
  
• In-vivo-Bioimaging-as-a-Novel-Strategy-to-Detect-Doxorubicin-Induced-Damage-to-Gonadal-Blood-Vessels-pone.0023492.s004.ogv 5分14秒, 480 × 336；11.62 MB
  
• 
  Irofulven.png 4,299 × 650；48 KB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s008.ogv 20秒, 512 × 464；1.41 MB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s009.ogv 30秒, 512 × 465；4.62 MB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s010.ogv 13秒, 512 × 464；357 KB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s011.ogv 20秒, 640 × 480；217 KB
  
• Irvalec-Inserts-into-the-Plasma-Membrane-Causing-Rapid-Loss-of-Integrity-and-Necrotic-Cell-Death-in-pone.0019042.s012.ogv 20秒, 1,281 × 961；989 KB
  
• 
  Ivosidenib.svg 512 × 385；8 KB
  
• 
  Leptomycin B.svg 2,558 × 986；4 KB
  
• 
  Linifanib skeletal.svg 314 × 133；30 KB
  
• 
  Lobaplatin.svg 268 × 101；48 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s1.ogv 14秒, 143 × 143；279 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s10.ogv 13秒, 110 × 110；131 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s11.ogv 46秒, 72 × 72；86 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s12.ogv 37秒, 72 × 72；152 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s13.ogv 36秒, 72 × 72；109 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s14.ogv 41秒, 160 × 160；1.15 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s15.ogv 21秒, 120 × 120；435 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s16.ogv 35秒, 200 × 200；900 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s17.ogv 50秒, 140 × 140；1.04 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s18.ogv 53秒, 130 × 130；1.18 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s2.ogv 48秒, 230 × 230；954 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s3.ogv 31秒, 133 × 133；734 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s4.ogv 1分12秒, 120 × 120；1.33 MB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s5.ogv 58秒, 150 × 150；856 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s6.ogv 16秒, 130 × 130；318 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s7.ogv 33秒, 90 × 90；50 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s8.ogv 29秒, 127 × 127；390 KB
  
• Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s9.ogv 12秒, 200 × 200；620 KB
  
• 
  Lurbinectedin structure.svg 512 × 357；13 KB
  
• 
  Lurbinectedin.png 1,647 × 1,453；141 KB
  
• 
  Mecanisme d'acció Pyr1.jpg 462 × 577；52 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s006.ogv 7.3秒, 264 × 203；322 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s007.ogv 9.2秒, 264 × 203；280 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s008.ogv 11秒, 198 × 152；210 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s009.ogv 11秒, 198 × 152；277 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s010.ogv 15秒, 174 × 133；205 KB
  
• Mechanism-of-Cancer-Cell-Death-Induced-by-Depletion-of-an-Essential-Replication-Regulator-pone.0036372.s011.ogv 15秒, 174 × 133；87 KB
  
• Methyl-Sulfone-Induces-Loss-of-Metastatic-Properties-and-Reemergence-of-Normal-Phenotypes-in-a-pone.0011788.s001.ogv 6.0秒, 312 × 240；727 KB
  
• Methyl-Sulfone-Induces-Loss-of-Metastatic-Properties-and-Reemergence-of-Normal-Phenotypes-in-a-pone.0011788.s002.ogv 1.9秒, 312 × 240；358 KB
  
• Methylsulfonylmethane-Suppresses-Breast-Cancer-Growth-by-Down-Regulating-STAT3-and-STAT5b-Pathways-pone.0033361.s001.ogv 29秒, 480 × 320；2.47 MB
  
• Methylsulfonylmethane-Suppresses-Breast-Cancer-Growth-by-Down-Regulating-STAT3-and-STAT5b-Pathways-pone.0033361.s002.ogv 29秒, 480 × 320；1.39 MB
  
• 
  Mezigdomide.svg 512 × 200；9 KB
  
• 
  Monomethylauristatin E.svg 512 × 249；73 KB
  
• 
  Monomethylauristatin F.svg 1,105 × 600；33 KB
  
• 
  Nandrolone 17-bis(2-chloroethyl)carbamate.svg 1,670 × 990；29 KB
  
• 
  Navitoclax.svg 2,625 × 1,500；40 KB
  
• 
  Nedaplatin 3D BS.png 2,385 × 1,878；477 KB
  
• Oblongifolin-C-inhibits-metastasis-by-up-regulating-keratin-18-and-tubulins-srep10293-s2.ogv 14秒, 1,365 × 1,024；52.06 MB
  
• Oblongifolin-C-inhibits-metastasis-by-up-regulating-keratin-18-and-tubulins-srep10293-s3.ogv 14秒, 1,365 × 1,024；51.8 MB
  
• 
  Olutasidenib.svg 790 × 385；19 KB
  
• Oxytocin-evokes-a-pulsatile-PGE2-release-from-ileum-mucosa-and-is-required-for-repair-of-intestinal-srep11731-s2.ogv 44秒, 720 × 720；14.67 MB
  
• 
  P-Tosylaminocaprylchlormethylketon Synthese.svg 410 × 199；52 KB
  
• 
  Padeliporfin.png 1,767 × 1,944；161 KB
  
• 
  Pegdinetanib non-peptide structure.svg 541 × 183；39 KB
  
• 
  Picoplatin.png 1,126 × 872；15 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S1.ogv 0.6秒, 636 × 432；216 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S2.ogv 0.6秒, 636 × 432；151 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S3.ogv 0.6秒, 636 × 432；192 KB
  
• Playing-games-with-a-thrombus-a-dangerous-match.-Paradoxical-embolism-from-a-huge-central-venous-1476-7120-8-6-S4.ogv 0.6秒, 636 × 432；197 KB
  
• 
  Plicamycin.svg 2,576 × 1,705；27 KB
  
• 
  Porfimer Sodium.png 4,195 × 1,593；85 KB
  
• 
  Quisinostat.svg 512 × 242；6 KB
  
• 
  Repotrectinib 7VKN.png 2,000 × 1,887；865 KB
  
• 
  Salinosporamide A Biosynthesis.png 1,568 × 1,330；34 KB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S1.ogv 28秒, 400 × 250；390 KB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S2.ogv 28秒, 400 × 250；1.36 MB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S3.ogv 28秒, 400 × 250；639 KB
  
• Selective-anticancer-activity-of-a-hexapeptide-with-sequence-homology-to-a-non-kinase-domain-of-1476-4598-10-72-S4.ogv 28秒, 343 × 253；685 KB
  
• 
  Selinexor.svg 512 × 281；7 KB
  
• Semaphorin-3A-Suppresses-Tumor-Growth-and-Metastasis-in-Mice-Melanoma-Model-pone.0033633.s005.ogv 11秒, 176 × 144；515 KB
  
• Semaphorin-3A-Suppresses-Tumor-Growth-and-Metastasis-in-Mice-Melanoma-Model-pone.0033633.s006.ogv 11秒, 176 × 144；426 KB
  
• Semaphorin-3A-Suppresses-Tumor-Growth-and-Metastasis-in-Mice-Melanoma-Model-pone.0033633.s007.ogv 11秒, 176 × 144；413 KB
  
• 
  Streptovitacin A.svg 1,170 × 940；19 KB
  
• Structure-and-Function-of-ABCG2-Rich-Extracellular-Vesicles-Mediating-Multidrug-Resistance-pone.0016007.s005.ogv 2.4秒, 1,024 × 1,024；277 KB
  
• Structure-and-Function-of-ABCG2-Rich-Extracellular-Vesicles-Mediating-Multidrug-Resistance-pone.0016007.s006.ogv 3.0秒, 512 × 520；256 KB
  
• 
  STX-140.svg 167 × 118；22 KB
  
• 
  Tabla antineoplasicos.png 973 × 327；18 KB
  
• 
  Talampanel skeletal.svg 512 × 507；5 KB
  
• 
  Talirine skeletal.svg 1,207 × 561；18 KB
  
• 
  Targaprimir 96.svg 1,568 × 832；44 KB
  
• 
  Targaprimir-96-CA-Biotin (1).svg 1,568 × 1,249；57 KB
  
• 
  Targaprimir-96-CA-Biotin (2).svg 1,574 × 1,049；56 KB
  
• 
  Targaprimir-96-CA-Biotin (3).svg 1,574 × 1,049；59 KB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s2.ogv 13秒, 1,280 × 960；624 KB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s3.ogv 19秒, 1,280 × 960；615 KB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s4.ogv 19秒, 1,280 × 960；1.31 MB
  
• Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s5.ogv 19秒, 1,280 × 960；1.36 MB
  
• 
  Tesirine skeletal.svg 1,216 × 660；21 KB
  
• Thymosin-β10-Expression-Driven-by-the-Human-TERT-Promoter-Induces-Ovarian-Cancer-Specific-Apoptosis-pone.0035399.s001.ogv 26秒, 480 × 480；4.58 MB
  
• 
  Trabectedin Biosynthesis.png 11,033 × 7,093；2.96 MB
  
• 
  Trabectedin labeled-rings.gif 1,053 × 758；14 KB
  
• 
  Trabectedin structure.svg 512 × 385；13 KB
  
• 
  Trabectedin.svg 491 × 395；34 KB
  
• 
  U-11,555 image.png 1,211 × 843；16 KB
  
• 
  Uvaricin.svg 2,261 × 1,569；3 KB
  
• 
  Vadimezan.png 561 × 438；7 KB
  
• 
  Vapreotide.svg 512 × 461；72 KB
  
• 
  Vintafolide.svg 512 × 497；131 KB
  
• 
  Y-90 tacatuzumab tetraxetan structure.svg 292 × 174；64 KB